Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Diluted EPS of $1.11 per share (loss) for fiscal year 2025.
BRAINSTORM CELL THERAPEUTICS INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.11 | +51.9% |
| 2024 | -$2.31 | +61.5% |
| 2023 | -$6.00 | -809.1% |
| 2022 | -$0.66 | +2.9% |
| 2021 | -$0.68 | +36.4% |
| 2020 | -$1.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.19 | +62.7% | +44.1% |
| June 30, 2025 | -$0.34 | +43.3% | +24.4% |
| March 31, 2025 | -$0.45 | +40.0% | +11.8% |
| September 30, 2024 | -$0.51 | -13.3% | +15.0% |
| June 30, 2024 | -$0.60 | -361.5% | +20.0% |
| March 31, 2024 | -$0.75 | -435.7% | -66.7% |
| September 30, 2023 | -$0.45 | -136.8% | -246.2% |
| June 30, 2023 | -$0.13 | +31.6% | +7.1% |
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +51.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, BRAINSTORM CELL THERAPEUTICS INC.’s diluted eps has declined by 3.7% (from $1.07 per share (loss) to $1.11 per share (loss)).
- The most recent figure is from BRAINSTORM CELL THERAPEUTICS INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: